Despite the continued advancement in the efficacy and convenience of antiretroviral therapy (ART), counseling patients about the metabolic side effects of medications remains an integral task for clinicians. This retrospective study examines changes in weight and renal function in patients receiving long-acting injectable cabotegravir-rilpivirine (LAI CAB/RPV) compared to oral regimens in a real-world setting. In this small set of patients, LAI CAB/RPV led to less weight gain compared to oral integrase inhibitor-based regimens. However, there was no significant change in the estimated glomerular filtration rate (eGFR) between patients who were started on LAI CAB/RPV and those who continued to receive oral regimens with or without tenofovir alafenamide (TAF).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879144 | PMC |
| http://dx.doi.org/10.7759/cureus.78384 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Real-World Impact of Long-Acting Injectable Cabotegravir-Rilpivirine on Weight and Renal Function.
Cureus
February 2025
Department of Medicine, Division of Infectious Diseases, University of Connecticut, Farmington, USA.
Despite the continued advancement in the efficacy and convenience of antiretroviral therapy (ART), counseling patients about the metabolic side effects of medications remains an integral task for clinicians. This retrospective study examines changes in weight and renal function in patients receiving long-acting injectable cabotegravir-rilpivirine (LAI CAB/RPV) compared to oral regimens in a real-world setting. In this small set of patients, LAI CAB/RPV led to less weight gain compared to oral integrase inhibitor-based regimens.
View Article and Find Full Text PDFDrug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in Poland.
Microorganisms
February 2025
Hospital for Infectious Diseases in Warsaw, Wolska 37 Street, 01-201 Warsaw, Poland.
HIV subtype A6 with the L74I polymorphism, which increases the risk of cabotegravir/rilpivirine treatment failure, causes more and more infections in Poland. In this multicenter, observational, cross-sectional study (2023-2024), we analyzed viral subtypes and drug-resistance mutations to drugs used for long-acting injectable antiretroviral treatment and pre-exposure prophylaxis. Among 357 people with HIV, 247 (69%) were Polish nationals, and 102 (29%) were from former Soviet Union countries.
View Article and Find Full Text PDFTransient Viremia Among People with HIV Receiving Injectable Cabotegravir Plus Rilpivirine.
AIDS Res Hum Retroviruses
February 2025
Division of Infectious Diseases, Children's National Hospital, Washington, District of Columbia, USA.
Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) provides an effective treatment option for people with HIV (PWH). Studies suggest that PWH on LAI CAB/RPV may experience isolated episodes of transient viremia (HIV RNA > 20 copies/mL) defined as virologic blips (VB). The risk factors for VB in PWH receiving LAI CAB/RPV are limited.
View Article and Find Full Text PDFEfficacy, Safety and Retention in Care Among Adolescents and Youth With HIV on Long-Acting Injectable Cabotegravir/Rilpivirine Treatment: Real-World Observational Cohort Outcomes.
Pediatr Infect Dis J
January 2025
From the Division of Infectious Diseases.
Background: Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) can improve adherence among adolescents and youth with HIV (AYHIV). We evaluated LAI CAB/RPV treatment outcomes among AYHIV.
Methods: An observational cohort study of AYHIV <25 years initiated LAI CAB/RPV from October 2021 to June 2024 as a standard of care.
CROI 2024: The Challenges of Sustained Viral Suppression, Advanced HIV Disease, and Ending the HIV Epidemic Targets.
Top Antivir Med
August 2024
New York Blood Center, New York, New York, USA.
Data on the HIV care cascade demonstrated challenges in achieving Ending the HIV Epidemic (EHE) targets across all 18 EHE focus metropolitan areas, but innovative adherence interventions using point-of-care tenofovir testing and motivational interviewing support care cascade outcomes in Namibia and South Africa, respectively. Data on treatment with long-acting injectable (LAI) antiretroviral therapy (ART) demonstrated high acceptability, retention, and virologic suppression including in groups that were not well represented in clinical trials including persons born female and persons with detectable viral loads. The adjuvanted hepatitis B vaccine appeared to be safe and appeared to be superior to conventional hepatitis B vaccines in persons with HIV (PWH) who were prior nonresponders to the hepatitis B vaccine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!